Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose

Blood Cells, Molecules, and Diseases

Volumn 59, Issue , 2016, Pages 100-105

  Drakou, Athina ^a   Margeli, Alexandra ^b   Theodorakopoulou, Stamatia ^a   Agrogiannis, Ioannis ^a   Poziopoulos, Christos ^b   Papassotiriou, Ioannis ^b   Vlahakos, Demetrios V ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Chronic kidney disease; Ferric carboxymaltose; Hepcidin 25; Intravenous iron administration; STfR

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; HEPCIDIN; HEPCIDIN 25; INTERLEUKIN 6; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; FERRIC ION; HEPCIDIN 25, HUMAN; MALTOSE;

AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS; DISEASE SEVERITY; DRUG RESPONSE; ERYTHROPOIESIS; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; MIDDLE AGED; PROCEDURES; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; DIALYSIS; DRUG MONITORING; ERYTHROPOIESIS; FEMALE; FERRIC COMPOUNDS; HEPCIDINS; HUMANS; MALE; MALTOSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TRANSFERRIN; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY;

EID: 84968830701     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2016.05.006     Document Type: Article

References (36)

1. National Kidney Foundation, et al. Am. J. Kidney Dis. 2004, 43:S1-S290.
2. Eschbach J.W., Adamson J.W. Anemia of end-stage-renal-disease (ESRD). Kidney Int. 1985, 28:1-5.
3. Kidney Disease Improving Global Outcomes (KDIGO) Clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012, 2:292-298.
4. Freburger J.K., Ng L.J., Bradbury B.D., et al. Changing patterns of anemia management in US hemodialysis patients. Am. J. Med. 2012, 125:906-914.
5. Gill K.S., Muntner P., Layafette R., et al. Red blood cell transfusion use in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2013, 28:1504-1515.
6. Minutolo R., Locatelli F., Gallieni M., et al. Anaemia management in nondialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol. Dial. Transplant. 2013, 28:3035-3045.
7. Weinberg E.D. Iron loading and disease surveillance. Emerg. Infect. Dis. 1999, 5:346-352.
8. Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352:1011-1023.
9. Skikne B.S., Punnonen K., Caldron P.H., et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and sTfR/log ferritin index. Am. J. Hematol. 2011, 86:923-927.
10. Park C.H., Valore E.V., Waring A.J., et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276:7806-7810.
11. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfidebonded human peptide exhibits antimicrobial activity. FEBS Lett. 2000, 480:147-150.
12. Łukaszyk E., Łukaszyk M., Koc-Zórawska E., et al. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press. Res. 2015, 40:366-373.
13. Cheng H.L., Bryant C.E., Rooney K.B., et al. Iron, hepcidin and inflammatory status of young healthy overweight and obese women in Australia. PLoS One 2013, 8:1-6.
14. Mupfudze T.G., Stoltzfus R.J., Rukobo S., et al. Plasma concentrations of hepcidin in anemic Zimbabwean infants. PLoS One 2015, 10:1-15.
15. Ashby D.R., Gale D.P., Busbridge M., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009, 27:504-510. Journal of Clinical Laboratory Analysis 2013.
16. Troutt J.S., Butterfield A.M., Konrad R.J. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J. Clin. Lab. Anal. 2013, 27:504-510.
17. Martinelli N., Traglia M., Campostrini N., et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PloS ONE 2012, 7:1-6.
18. Macdougall I.C., Bock A.H., Carrera F., et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29:2075-2084.
19. Steensma D.P., Sasu B.J., Sloan J.A., et al. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015, 125:3669-3671.
20. Marathias K.P., Agrogiannis B., Mavromoustakas T., et al. Hematocrit lowering effect of renin angiotensin system with angiotensin converting enzyme inhibition and angiotensin receptor blockers. Curr. Top. Med. Chem. 2004, 4:483-486.
21. Takasawa K., Takaeda C., Maeda T., et al. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Nutrients 2015, 7:103-118.
22. Chand S., Ward D.G., Ng Z.Y., et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J. Nephrol. 2015, 28:81-88.
23. Lasocki S., Baron G., Driss F., et al. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010, 36:1044-1048.
24. Tessitore N., Girelli D., Campostrini N., et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol. Dial. Transplant. 2010, 25:3996-4002.
25. Papanikolaou G., Tzilianos M., Christakis J., et al. Hepcidin in iron overload disorders. Blood 2005, 105:4103-4105.
26. Petterson T., Kivivuori S.M., Siimes M.A. Is serum transferrin receptor useful for detecting iron deficiency inn anemic patients with chronic inflammatory disease?. Br. J. Rheumatol. 1994, 33:740-744.
27. Panichi V., Migliori M., De Pietro S., et al. C reactive protein in patients with chronic renal diseases. Ren. Fail. 2001, 23:551-562.
28. Rodriguez R.C., Jung C.L., Gabaya V., et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect. Immun. 2014, 82:745-752.
29. Nemeth E., Valore E.V., Territo M., et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
30. Kemna E., Pickkers P., Nemeth E., et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106:1864-1866.
31. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
32. Ashby D.R., Gale D.P., Busbridge M., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009, 75:976-981.
33. Artunc F., Risler T. Nephrol. Dial. Transplant. 2007, 22:2900-2908.
34. Kautz L., Jung G., Du X., et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood 2015, 126:2031-2037.
35. Honda H., Kobayashi Y., Onuma S., et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS ONE 2016, 11(3).
36. Ciniselli C.M., De Bortoli M., Taverna E., et al. Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Rev. Proteomics 2015, 12:695-701.